JP2022529917A5 - - Google Patents

Info

Publication number
JP2022529917A5
JP2022529917A5 JP2021560988A JP2021560988A JP2022529917A5 JP 2022529917 A5 JP2022529917 A5 JP 2022529917A5 JP 2021560988 A JP2021560988 A JP 2021560988A JP 2021560988 A JP2021560988 A JP 2021560988A JP 2022529917 A5 JP2022529917 A5 JP 2022529917A5
Authority
JP
Japan
Prior art keywords
mir
inhibitor
patient
pharmaceutical composition
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021560988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/060888 external-priority patent/WO2020212586A1/en
Publication of JP2022529917A publication Critical patent/JP2022529917A/ja
Publication of JP2022529917A5 publication Critical patent/JP2022529917A5/ja
Pending legal-status Critical Current

Links

JP2021560988A 2019-04-18 2020-04-17 ガンの処置及び予後のための方法 Pending JP2022529917A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19305507 2019-04-18
EP19305507.6 2019-04-18
EP19305955.7 2019-07-18
EP19305955 2019-07-18
PCT/EP2020/060888 WO2020212586A1 (en) 2019-04-18 2020-04-17 Methods for the treatment and prognosis of cancer

Publications (2)

Publication Number Publication Date
JP2022529917A JP2022529917A (ja) 2022-06-27
JP2022529917A5 true JP2022529917A5 (https=) 2023-02-03

Family

ID=70228072

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560988A Pending JP2022529917A (ja) 2019-04-18 2020-04-17 ガンの処置及び予後のための方法

Country Status (4)

Country Link
US (1) US20220211741A1 (https=)
EP (1) EP3956474A1 (https=)
JP (1) JP2022529917A (https=)
WO (1) WO2020212586A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113160979A (zh) * 2020-12-18 2021-07-23 北京臻知医学科技有限责任公司 基于机器学习的肝癌患者临床预后的预测方法
CN119694399B (zh) * 2024-11-26 2025-11-11 佛山大学 基于深度神经网络的癌症预后评估与靶点识别方法及系统

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5132432A (en) 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5338854A (en) 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6048616A (en) 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
US5571018A (en) 1994-11-23 1996-11-05 Motorola, Inc. Arrangement for simulating indirect fire in combat training
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6617583B1 (en) 1998-09-18 2003-09-09 Massachusetts Institute Of Technology Inventory control
US6114038A (en) 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6855202B2 (en) 2001-11-30 2005-02-15 The Regents Of The University Of California Shaped nanocrystal particles and methods for making the same
AU4701200A (en) 1999-05-07 2000-11-21 Quantum Dot Corporation A method of detecting an analyte using semiconductor nanocrystals
US6225198B1 (en) 2000-02-04 2001-05-01 The Regents Of The University Of California Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
US6306736B1 (en) 2000-02-04 2001-10-23 The Regents Of The University Of California Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
JP2004500109A (ja) 2000-03-22 2004-01-08 クァンタム・ドット・コーポレイション ビーズベースの核酸アッセイにおける半導体ナノクリスタルの使用方法
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
JP2003535063A (ja) 2000-06-01 2003-11-25 ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティー 放射線医薬としてのナノ粒子のバイオコンジュゲート
EP1311487B1 (en) 2000-08-04 2008-11-26 Molecular Probes, Inc. Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US6709929B2 (en) 2001-06-25 2004-03-23 North Carolina State University Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
JP4567436B2 (ja) 2001-07-20 2010-10-20 ライフ テクノロジーズ コーポレーション 発光ナノ粒子およびそれらの調製方法
CA2486658C (en) 2002-05-31 2014-07-29 The Regents Of The University Of California Method for efficient rna interference in mammalian cells
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP2302055B1 (en) * 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2007076128A2 (en) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
JP5700911B2 (ja) 2005-12-23 2015-04-15 ナノストリング テクノロジーズ，インコーポレーテッド 配向され、固定化された巨大分子を含む組成物とその製造法
CA2687292C (en) 2007-04-10 2017-07-04 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US8519115B2 (en) 2008-08-14 2013-08-27 Nanostring Technologies, Inc. Stable nanoreporters
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
US8846316B2 (en) * 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer

Similar Documents

Publication Publication Date Title
Liu et al. The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implications
Zhang et al. Long non-coding RNAs in Oral squamous cell carcinoma: biologic function, mechanisms and clinical implications
Yadav et al. LncRNAs associated with glioblastoma: from transcriptional noise to novel regulators with a promising role in therapeutics
AU2012322788B2 (en) Micrornas in neurodegenerative disorders
Watanabe et al. Genome structure‐based screening identified epigenetically silenced microRNA associated with invasiveness in non‐small‐cell lung cancer
Yan et al. Circular RNA PVT1 promotes metastasis via regulating of miR‐526b/FOXC2 signals in OS cells
Zhang et al. MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma
Wang et al. MALAT1 lncRNA induces autophagy and protects brain microvascular endothelial cells against oxygen–glucose deprivation by binding to miR-200c-3p and upregulating SIRT1 expression
US8785414B2 (en) Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjögren's syndrome
US10495648B2 (en) Methods of treating liver fibrosis
Qu et al. miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment
Choi et al. Dual-strand tumor suppressor miR-193b-3p and-5p inhibit malignant phenotypes of lung cancer by suppressing their common targets
CN101939446A (zh) 人类卵巢癌中的微小rna特征
EP2683411B1 (en) Methods of using microrna-26a to promote angiogenesis
Katsushima et al. Long non-coding RNAs in brain tumors
Ma et al. KDM5A silencing transcriptionally suppresses the FXYD3‐PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR‐433 up‐regulation
Kuai et al. Long non‐coding RNAs in diabetic wound healing: Current research and clinical relevance
Zhou et al. Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p.
Ben-Hamo et al. hsa-miR-9 controls the mobility behavior of glioblastoma cells via regulation of MAPK14 signaling elements
JP2022529917A5 (https=)
US11013754B2 (en) Compositions and methods for treating cancer
Saadh et al. MicroRNA as key players in hepatocellular carcinoma: insights into their role in metastasis
Zhang et al. Downregulation of MiR-1538 promotes proliferation and metastasis of colorectal cancer by targeting DNMT3A
Fath et al. Circular RNAs in neuroblastoma: Pathogenesis, potential biomarker, and therapeutic target
Roquid et al. Identification and validation of mRNA 3′ untranslated regions of DNMT3B and TET3 as novel competing endogenous RNAs of the tumor suppressor PTEN